Decision Resources' Updated Rheumatoid Arthritis Report Now Includes Forecast for Rigel Pharmaceuticals' Fostamatinib Disodium
Posted on: Thursday, 6 August 2009, 08:00 CDT
WALTHAM, Mass., Aug. 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, today released its updated Pharmacor Rheumatoid Arthritis report which now includes patient share and sales forecasts through 2018 for Rigel Pharmaceuticals' investigational novel oral agent, fostamatinib disodium (R788). The report update is based on Rigel Pharmaceuticals' recent announcement regarding additional Phase II clinical data for fostamatinib disodium.
The report finds that, owing to its impressive efficacy, the spleen tyrosine kinase (Syk) inhibitor fostamatinib disodium will likely precede TNF-alpha inhibitors such as Amgen/Wyeth/Takeda's Enbrel and Abbott/Eisai's Humira in the treatment cascade for rheumatoid arthritis. Phase II data shows that fostamatinib disodium's efficacy is comparable to that of currently-available biologic agents in patients with inadequate response to treatment with methotrexate. According to the report, if the agent is priced lower than currently-available biologics, physicians may be willing to prescribe fostamatinib disodium as an alternative to premium-priced biologics.
However, Decision Resources conservatively forecasts that fostamatinib disodium's patient share will reach up to 1.8 percent and it will garner major-market sales of $330 million in 2018.
"Fostamatinib disodium's patient share and sales will be considerably lower than our evaluation of the other novel oral agent in development for rheumatoid arthritis--Pfizer's Jak-3 inhibitor CP-690550," said Decision Resources Analyst Joanna Kim, M.Ed. "Fostamatinib disodium's impact is likely to be less than that of CP-690550 because of uncertainties about its efficacy in the TNF-refractory population and the absence of a head-to-head trial against a TNF-alpha inhibitor."
About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.
About Decision Resources, Inc.
Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Decision Resources Decision Resources, Inc. Christopher Comfort Elizabeth Marshall 781-296-2597 781-296-2563 ccomfort@dresources.com emarshall@dresources.comSOURCE Decision Resources
Source: PR Newswire
Related Articles
- Lodotra(TM) Shows a Sustained Reduction of Morning Stiffness in Patients With Rheumatoid Arthritis Treated With Lodotra(TM) for 12 Months
- Alliance Resource Partners, L.P. Reports Increases to 2007 Third Quarter Coal Sales Volumes, Revenues, Net Income and EBITDA; Posts Record Nine Month Financial and Operating Results; and Declares Quarterly Distribution of $0.56 Per Unit
- Three Studies Suggest Abbott's HUMIRA(R) (Adalimumab) May Improve Work Productivity in Patients With Rheumatoid Arthritis
- Concentrating on Extending the Shelf Life of Drugs Such As Antidepressants (the SSRIs and SNRIs), Anti-Tnf-Alpha Agents for Inflammatory Diseases, and Angiotensin II Antagonists Used in Cardiovascular Indications
- Preclinical Carotid Atherosclerosis in Patients With Rheumatoid Arthritis
- ZymoGenetics Reports Preliminary Positive Results From TACI-Ig Phase 1b Study in Patients With Rheumatoid Arthritis
- A unique approach providing lasting benefits for patients with rheumatoid arthritis
- HUMIRA(R) (Adalimumab) Shows Promise in Treating Patients With Rheumatoid Arthritis Who Previously Failed Anti-TNF Treatment
- Oakley Posts 29 Percent Increase In Earnings Per Share On Record Quarterly Net Sales Of $173.4 Million
- Human Genome Sciences Reports Results of a Phase 2 Clinical Trial of LymphoStat-B(TM) in Patients With Rheumatoid Arthritis
 |
 |
User Comments (0)
RSS Feeds